CRSPTxJPMorgan

CRISPR THERAPEUTICS –CONFIDENTIAL1© 2025 CRISPR Therapeutics |143rd Annual J.P. Morgan Healthcare ConferenceJanuary 14, 2025CRISPR THERAPEUTICS – CONFIDENTIAL2© 2025 CRISPR Therapeutics |2Forward-Looking Statements​This presentation and related materials may contain statements regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding any or all of the following: (i) CRISPR Therapeutics’ preclinical studies, clinical trials and pipeline products and programs, including, without limitation, manufacturing capabilities, status of such studies and trials, potential expansion into new indications and expectations regarding data, safety and efficacy generally